Background: Chimeric antigen receptor (CAR) T-cells have revolutionized the treatment of CD19- and B-cell maturation antigen-positive haematological malignancies. However, the effect of a CAR construct on the function of T-cells stimulated via their endogenous T-cell receptors (TCRs) has yet to be comprehensively investigated.

Methods: Experiments were performed to systematically assess TCR signalling and function in CAR T-cells using anti-mesothelin human CAR T-cells as a model system. CAR T-cells expressing the CD28 or 4-1BB costimulatory endodomains were manufactured and compared to both untransduced T-cells and CAR T-cells with a non-functional endodomain. These cell products were treated with staphylococcal enterotoxin B to stimulate the TCR, and in vitro functional assays were performed by flow cytometry.

Results: Increased proliferation, CD69 expression and IFNγ production were identified in CD8+ 4-1BBζ CAR T-cells compared to control untransduced CD8+ T-cells. These functional differences were associated with higher levels of phosphorylated ZAP70 after stimulation. In addition, these functional differences were associated with a differing immunophenotype, with a more than two-fold increase in central memory cells in CD8+ 4-1BBζ CAR T-cell products.

Conclusion: Our data indicate that the 4-1BBζ CAR enhances CD8+ TCR-mediated function. This could be beneficial if the TCR targets epitopes on malignant tissues or infectious agents, but detrimental if the TCR targets autoantigens.

Author Info: (1) Gene and Stem Cell Therapy Program Centenary Institute, Camperdown, NSW, Australia. Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Camperdown, NSW , Australia. Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. (2) Gene and Stem Cell Therapy Program Centenary Institute, Camperdown, NSW, Australia. Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. Cancer & Gene Regulation Laboratory Centenary Institute, Camperdown, NSW, Australia. (3) Gene and Stem Cell Therapy Program Centenary Institute, Camperdown, NSW, Australia. (4) Cell & Molecular Therapies, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. (5) Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. (6) Gene and Stem Cell Therapy Program Centenary Institute, Camperdown, NSW, Australia. j.rasko@centenary.org.au. Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. j.rasko@centenary.org.au. Cell & Molecular Therapies, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. j.rasko@centenary.org.au.